Anindya Roy, a researcher at the University of Washington Institute for Protein Design (IPD), has received a $250,000 grant from Washington Research Foundation (WRF) for continued development of an inhaled miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF), WRF has announced. According to WRF, Roy's miniprotein binds to the αvβ6 integrin, … [Read more...] about Washington Research Foundation awards grant for development of inhaled miniprotein for IPF
News
Rokote Labs gets €9 million for development of intranasal COVID vaccine
Rokote Laboratories, a spin out from the University of Helsinki and the University of Eastern Finland, has raised €9 million for development of an intranasal vaccine against the SARS-CoV-2 virus, the universities have announced. The funding, which includes €3.5 million from the Finnish Cultural Foundation, Ferring Ventures SA, and the Jenny and Antti Wihuri … [Read more...] about Rokote Labs gets €9 million for development of intranasal COVID vaccine
Atossa announces Phase 1/2a study of nebulized AT-H201
Atossa Therapeutics said that the Human Research Ethics Committee (HREC) of the Australian National Health and Medical Research Council (NHMRC) has okayed a Phase 1/2a clinical study of the company's nebulized AT-H201, which is "is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes." The … [Read more...] about Atossa announces Phase 1/2a study of nebulized AT-H201
PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment of multi-drug resistant Mycobacterium abscessus lung infections. Radboudumc research has demonstrated that inhaled … [Read more...] about PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
NDA for Levo Therapeutics’ intranasal carbetocin for Prader-Willi syndrome gets priority review designation
Levo Therapeutics announced that the FDA has accepted the company's NDA for LV-101 intranasal carbetocin for the treatment of excessive hunger associated with Prader-Willi syndrome (PWS) and has granted the NDA Priority Review designation, with a decision about approval expected by the end of 2021. LV-101 for PWS was granted Fast Track designation by the FDA in 2019. … [Read more...] about NDA for Levo Therapeutics’ intranasal carbetocin for Prader-Willi syndrome gets priority review designation
M8 Pharmaceuticals gets Brazilian and Mexican rights to Marinomed’s Carragelose nasal spray
M8 Pharmaceuticals said that it has acquired exclusive rights to market Marinomed's Carragelose nasal spray in Brazil and Mexico. The company will market the product in those countries as Barlo nasal spray for the prevention of respiratory viruses. Carragelose nasal sprays are currently marketed over 40 countries, including Italy, Austria, Canada, China, and … [Read more...] about M8 Pharmaceuticals gets Brazilian and Mexican rights to Marinomed’s Carragelose nasal spray
TGA fines Starpharma more than $93,000 over Viraleze nasal spray claims
The Australian Therapeutic Goods Administration has issued 7 infringement notices to Starpharma regarding advertising of the company's Viraleze astodrimer sodium antiviral nasal spray, with fines totaling $93,240. The news comes shortly after after the UK Medicines and Healthcare products Regulatory Agency questioned claims regarding Viraleze, prompting the company's … [Read more...] about TGA fines Starpharma more than $93,000 over Viraleze nasal spray claims
Inhalation Sciences announces proof-of-concept project with new mouse exposure model
Inhalation Sciences (ISAB) announced that its CRO division, Inhalation Research Services (IRS), has signed an agreement with "an innovative US pharma company that is developing novel mRNA therapies for the treatment of cystic fibrosis and other pulmonary diseases" for a proof-of-concept project utilizing ISAB's PreciseInhale aerosol generating system. The … [Read more...] about Inhalation Sciences announces proof-of-concept project with new mouse exposure model
FluGen gets funding from US Department of Defense for intranasal flu vaccine
FluGen said that it has received an $11.4 million grant from the United States Department of Defense for a Phase 1b study to evaluate the ability of its M2SR intranasal flu vaccine to protect against a variety of flu strains, including those like H3N2 that are mismatched to current vaccines. In February 2019, FluGen announced that a Phase 2 trial of the M2SR vaccine … [Read more...] about FluGen gets funding from US Department of Defense for intranasal flu vaccine
Savara initiates new Phase 3 trial of molgramostim inhaled GM-CSF for aPAP
Savara has announced the initiation of the Phase 3 IMPALA-2 clinical trial of molgramostim inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In December 2020, the company stopped development of the AeroVanc vancomycin DPI and Apulmiq (Linhaliq) inhaled … [Read more...] about Savara initiates new Phase 3 trial of molgramostim inhaled GM-CSF for aPAP